SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Financials Shenzhen New Industries Biomedical Engineering Co., Ltd.
Equities
300832
CNE100003T39
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 77.83 CNY | +1.18% |
|
+10.08% | -0.47% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 54,455 | 34,652 | 39,416 | 61,443 | 61,152 | - | - |
| Enterprise Value (EV) 1 | 54,455 | 34,652 | 38,934 | 60,397 | 58,875 | 57,699 | 59,021 |
| P/E ratio | 55.5 x | 35.6 x | 29.7 x | 37.2 x | 29.7 x | 23.4 x | 18.9 x |
| Yield | - | 1.36% | 1.4% | 1.28% | 1.6% | 2.01% | 2.33% |
| Capitalization / Revenue | 24.8 x | 13.6 x | 12.9 x | 15.6 x | 12.4 x | 9.89 x | 8.02 x |
| EV / Revenue | 24.8 x | 13.6 x | 12.8 x | 15.4 x | 12 x | 9.33 x | 7.74 x |
| EV / EBITDA | 45.8 x | 27.8 x | 26.3 x | 31.3 x | 23.7 x | 18.5 x | 15.4 x |
| EV / FCF | - | - | 69.5 x | 55.1 x | 36.1 x | 29.5 x | 23.5 x |
| FCF Yield | - | - | 1.44% | 1.81% | 2.77% | 3.39% | 4.25% |
| Price to Book | 11.3 x | 6.17 x | 6.16 x | 8.14 x | 6.97 x | 5.46 x | 4.47 x |
| Nbr of stocks (in thousands) | 783,465 | 786,659 | 786,126 | 785,719 | 785,719 | - | - |
| Reference price 2 | 69.51 | 44.05 | 50.14 | 78.20 | 77.83 | 77.83 | 77.83 |
| Announcement Date | 3/30/21 | 4/21/22 | 4/6/23 | 4/11/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,195 | 2,545 | 3,047 | 3,930 | 4,917 | 6,183 | 7,624 |
| EBITDA 1 | 1,190 | 1,248 | 1,479 | 1,928 | 2,487 | 3,113 | 3,827 |
| EBIT 1 | 1,099 | 1,137 | 1,504 | 1,895 | 2,338 | 2,976 | 3,704 |
| Operating Margin | 50.05% | 44.69% | 49.35% | 48.23% | 47.55% | 48.14% | 48.59% |
| Earnings before Tax (EBT) 1 | 1,097 | 1,136 | 1,501 | 1,893 | 2,361 | 3,000 | 3,718 |
| Net income 1 | 939.1 | 973.7 | 1,328 | 1,654 | 2,060 | 2,610 | 3,243 |
| Net margin | 42.79% | 38.25% | 43.58% | 42.08% | 41.9% | 42.21% | 42.54% |
| EPS 2 | 1.252 | 1.239 | 1.689 | 2.104 | 2.622 | 3.321 | 4.128 |
| Free Cash Flow 1 | - | - | 559.8 | 1,096 | 1,630 | 1,957 | 2,508 |
| FCF margin | - | - | 18.37% | 27.9% | 33.15% | 31.65% | 32.9% |
| FCF Conversion (EBITDA) | - | - | 37.85% | 56.86% | 65.53% | 62.87% | 65.54% |
| FCF Conversion (Net income) | - | - | 42.16% | 66.29% | 79.12% | 74.98% | 77.32% |
| Dividend per Share 2 | - | 0.6000 | 0.7000 | 1.000 | 1.247 | 1.564 | 1.816 |
| Announcement Date | 3/30/21 | 4/21/22 | 4/6/23 | 4/11/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|
| Net sales 1 | - | 989.3 | 1,865 | - | 1,022 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | 459.8 | 865.5 | 501.4 | 528.5 |
| Operating Margin | - | 46.48% | 46.4% | - | 51.73% |
| Earnings before Tax (EBT) 1 | - | 458.8 | 864.3 | 501.3 | 527.5 |
| Net income | 355.1 | 394.9 | 750 | - | - |
| Net margin | - | 39.92% | 40.21% | - | - |
| EPS | 0.4517 | 0.5025 | 0.9542 | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/27/23 | 8/24/23 | 8/24/23 | 10/26/23 | 4/11/24 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 482 | 1,047 | 2,278 | 3,453 | 2,131 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 560 | 1,096 | 1,630 | 1,957 | 2,508 |
| ROE (net income / shareholders' equity) | 22.4% | 18.9% | 21.9% | 23.7% | 23.2% | 23.9% | 24.2% |
| ROA (Net income/ Total Assets) | 21.4% | 17% | 18.9% | - | 21.3% | 22.4% | 22.2% |
| Assets 1 | 4,382 | 5,721 | 7,015 | - | 9,661 | 11,665 | 14,588 |
| Book Value Per Share 2 | 6.130 | 7.130 | 8.140 | 9.600 | 11.20 | 14.30 | 17.40 |
| Cash Flow per Share 2 | 1.250 | 0.9800 | 1.220 | 1.810 | 2.750 | 3.050 | 3.750 |
| Capex 1 | 253 | 343 | 403 | 322 | 346 | 384 | 596 |
| Capex / Sales | 11.53% | 13.46% | 13.21% | 8.2% | 7.04% | 6.21% | 7.82% |
| Announcement Date | 3/30/21 | 4/21/22 | 4/6/23 | 4/11/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
77.83
CNY
Average target price
84.5
CNY
Spread / Average Target
+8.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.47% | 8.46B | |
| -1.29% | 12.64B | |
| +5.68% | 5.66B | |
| +22.61% | 5.27B | |
| -2.03% | 4.49B | |
| -53.56% | 3.11B | |
| +19.30% | 2.87B | |
| +33.07% | 2.31B | |
| -8.42% | 2.23B | |
| -3.55% | 1.89B |
- Stock Market
- Equities
- 300832 Stock
- Financials Shenzhen New Industries Biomedical Engineering Co., Ltd.
